Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)John M.S. Bartlett, Christopher Poole, Janet Dunn et al.|The Lancet Oncology|2010Cited by 127